Peptide Protocol
Peptide Protocol
 App Store

Dihexa: the complete guide

Dihexa is an orally bioavailable angiotensin IV analog designed to cross the blood–brain barrier and potentiate hepatocyte growth factor (HGF) signaling. Preclinical work in rodent models supports effects on synaptogenesis and cognition.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassAngiotensin IV analog (HGF potentiator)
Half-lifeApproximately 2–3 hours (oral bioavailable)
Typical dose8–45 mg oral once daily (preclinical and early research protocols)
CategoryCognition / nootropic
Research useCognition research, synaptogenesis, neurodegenerative research
FDA statusNot FDA approved. Research use only. No approved human clinical program as of 2026.

How Dihexa works

Dihexa potentiates HGF / c-Met signaling in the CNS, promoting dendritic spine formation and synaptogenesis in preclinical models. Human data are very limited.

Typical Dihexa dosage

Commonly reported research ranges: 8–45 mg oral once daily (preclinical and early research protocols).

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

Administration

Dihexa is taken orally — no reconstitution is required. Follow the manufacturer's guidance for liquid or capsule dosing.

Half-life and administration frequency

Approximately 2–3 hours (oral bioavailable).

This half-life informs how often Dihexa is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common Dihexa stacks

Storage and handling

Oral, room temperature.

FDA and regulatory status

Not FDA approved. Research use only. No approved human clinical program as of 2026.

Dihexa clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your Dihexa protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is Dihexa?

Dihexa is an orally bioavailable angiotensin IV analog designed to cross the blood–brain barrier and potentiate hepatocyte growth factor (HGF) signaling. Preclinical work in rodent models supports effects on synaptogenesis and cognition.

How does Dihexa work?

Dihexa potentiates HGF / c-Met signaling in the CNS, promoting dendritic spine formation and synaptogenesis in preclinical models. Human data are very limited.

What is a typical Dihexa dose?

Commonly reported ranges are 8–45 mg oral once daily (preclinical and early research protocols). This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of Dihexa?

Approximately 2–3 hours (oral bioavailable). This influences how often it is taken.

Does Dihexa require reconstitution?

Dihexa is not handled as a standard lyophilized injectable reconstitution page in this database. Follow the manufacturer, study protocol, or clinician instructions for the specific formulation.

What are the side effects of Dihexa?

Limited human safety data; Potential effects on HGF-sensitive tissues (e.g., hepatic) are incompletely characterized; Theoretical oncogenicity concerns given HGF biology.

Is Dihexa FDA approved?

Not FDA approved. Research use only. No approved human clinical program as of 2026.

Are there clinical trials for Dihexa?

Registered or published clinical-trial sources for Dihexa are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. Dihexa / angiotensin IV analog literature — National Library of Medicine. Primary preclinical research on dihexa and HGF/c-Met signaling
  2. McCoy et al. — Dihexa cognition and synaptogenesis — PubMed. Foundational preclinical research on dihexa in cognition models
  3. Dihexa / PNB-0408 clinical records — ClinicalTrials.gov. Registered studies — very limited

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.